Early explosive force reduction associated with exercise-induced muscle damage.
This study was aimed to analyze the loss of muscle explosive force in the early phase of eccentric exercise-induced damage, and its possible relationships with muscle soreness and blood creatine kinase (CK) levels. Squat jump (SJ) and countermovement jump (CMJ) heights decreased in response to an eccentric exercise (120 eccentric actions of the knee extensors), with reductions that persisted at least for 24 h. The SJ/CMJ ratio was not significantly modified. Blood CK levels changed significantly over time and CK activity was significantly higher at 6 and at 24 h when compared to values obtained immediately after the eccentric exercise. Muscle soreness perceived at 6 h was slightly higher than that experienced just after finalizing the exercise and reached a clearly upper value at 24 h. A highly significant relationship between SJ and CMJ height loss was observed. CK activity at 24 h was significantly related to the SJ height loss at 6 h and to both the SJ height loss and the CMJ height loss immediately after the exercise. In summary, eccentric exercise induced a reduction in the explosive force generating capacity that affected in a similar way the pure concentric jump (SJ) and the jump eliciting the stretch-shortening cycle (CMJ). Results obtained suggest that CK activity is a better predictor of explosive force reduction than soreness, at least when values close to the peak are used.
García-López
D
D
Department of Physiology, University of León, Campus Universitario, 24071 León, Spain.
de Paz
J A
JA
Jiménez-Jiménez
R
R
Bresciani
G
G
De Souza-Teixeira
F
F
Herrero
J A
JA
Alvear-Ordenes
I
I
González-Gallego
J
J
D000328:Adult; D003402:Creatine Kinase / Q000097:blood; D015444:Exercise / Q000502:physiology*; D006801:Humans; D007719:Knee Joint / Q000502:physiology; D008297:Male; D009119:Muscle Contraction / Q000502:physiology*; D010146:Pain / Q000503:physiopathology; D052097:Quadriceps Muscle / Q000293:injuries* / Q000502:physiology*
D003402:Creatine Kinase